MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- BIOCON - ACTAVIS (US)
BIOCON vs ACTAVIS (US) - Comparison Results
BIOCON 
Change
Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More
ACTAVIS (US)
Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
Financials
 BIOCON  ACTAVIS |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| BIOCON Mar-18 |
ACTAVIS Dec-14 |
BIOCON / ACTAVIS |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,188 | 19,110 | - | |
| Low | Rs | 305 | 11,656 | - | |
| Sales per share (Unadj.) | Rs | 68.7 | 3,441.1 | - | |
| Earnings per share (Unadj.) | Rs | 7.6 | -429.4 | - | |
| Cash flow per share (Unadj.) | Rs | 14.0 | 315.7 | - | |
| Dividends per share (Unadj.) | Rs | 1.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.1 | 0 | - | |
| Book value per share (Unadj.) | Rs | 86.3 | 7,463.7 | - | |
| Shares outstanding (eoy) | m | 600.00 | 265.90 | - | |
| Bonus/Rights/Conversions | IS | - | - | ||
| Price / Sales ratio | x | 10.9 | 4.5 | 243.0% | |
| Avg P/E ratio | x | 98.9 | -35.8 | -275.9% | |
| P/CF ratio (eoy) | x | 53.4 | 48.7 | 109.7% | |
| Price / Book Value ratio | x | 8.6 | 2.1 | 419.5% | |
| Dividend payout | % | 13.2 | 0 | - | |
| Avg Mkt Cap | Rs m | 447,900 | 4,090,334 | 11.0% | |
| No. of employees | `000 | 6.1 | 21.6 | 28.5% | |
| Total wages/salary | Rs m | 9,311 | 0 | - | |
| Avg. sales/employee | Rs Th | 6,705.8 | 42,360.8 | 15.8% | |
| Avg. wages/employee | Rs Th | 1,514.2 | 0 | - | |
| Avg. net profit/employee | Rs Th | 736.9 | -5,286.2 | -13.9% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 41,234 | 914,993 | 4.5% | |
| Other income | Rs m | 2,062 | -2,284 | -90.3% | |
| Total revenues | Rs m | 43,296 | 912,709 | 4.7% | |
| Gross profit | Rs m | 8,291 | 117,544 | 7.1% | |
| Depreciation | Rs m | 3,851 | 198,129 | 1.9% | |
| Interest | Rs m | 615 | 28,861 | 2.1% | |
| Profit before tax | Rs m | 5,887 | -111,730 | -5.3% | |
| Minority Interest | Rs m | 213 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | -8,196 | 0.0% | |
| Tax | Rs m | 1,569 | -5,744 | -27.3% | |
| Profit after tax | Rs m | 4,531 | -114,182 | -4.0% | |
| Gross profit margin | % | 20.1 | 12.8 | 156.5% | |
| Effective tax rate | % | 26.7 | 5.1 | 518.4% | |
| Net profit margin | % | 11.0 | -12.5 | -88.1% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 41,486 | 482,084 | 8.6% | |
| Current liabilities | Rs m | 21,413 | 351,581 | 6.1% | |
| Net working cap to sales | % | 48.7 | 14.3 | 341.3% | |
| Current ratio | x | 1.9 | 1.4 | 141.3% | |
| Inventory Days | Days | 64 | 58 | 110.2% | |
| Debtors Days | Days | 94 | 66 | 142.1% | |
| Net fixed assets | Rs m | 50,661 | 111,730 | 45.3% | |
| Share capital | Rs m | 3,000 | 0 | - | |
| Net worth | Rs m | 51,808 | 1,984,587 | 2.6% | |
| Long term debt | Rs m | 17,898 | 1,039,962 | 1.7% | |
| Total assets | Rs m | 99,897 | 3,637,094 | 2.7% | |
| Interest coverage | x | 10.6 | -2.9 | -368.2% | |
| Debt to equity ratio | x | 0.3 | 0.5 | 65.9% | |
| Sales to assets ratio | x | 0.4 | 0.3 | 164.1% | |
| Return on assets | % | 5.2 | -2.3 | -219.6% | |
| Return on equity | % | 8.7 | -5.8 | -152.0% | |
| Return on capital | % | 9.6 | -3.0 | -320.0% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 6,621 | 157,122 | 4.2% | |
| From Investments | Rs m | -6,840 | -376,211 | 1.8% | |
| From Financial Activity | Rs m | -2,397 | 211,376 | -1.1% | |
| Net Cashflow | Rs m | -2,612 | -7,713 | 33.9% | |
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 70.05 Rs / USD
Compare BIOCON With: MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare BIOCON With: GSK PHARMA FRESENIUS KABI ONCO. DR. DATSONS LABS FDC LTD. LUPIN
|
| |
Today's Market
Sensex Trades Higher; Ultratech Cement Surges on Strong Q4 Result(12:30 pm)
Stock markets in India are presently witnessing buying interest. The BSE Sensex is trading up by 151 points and the NSE Nifty is trading up by 56 points.
Related Views On News
BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)
Jan 28, 2019 | Updated on Jan 28, 2019For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.
BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)
Nov 9, 2018 | Updated on Nov 9, 2018For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.
Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)
Feb 2, 2018Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.
Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)
Jun 23, 2017Net Profit lower due to exceptional items in the previous year.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)
Apr 12, 2019This critical business strategy has enabled companies to scale their operations faster.
Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)
Apr 12, 2019Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.
My Master Series on How to Trade Election 2019(Profit Hunter)
Apr 16, 2019For 30 years he has watched how elections impact the markets, and practiced how to profit from it. Now he is here...telling you everything. Read on...
Election Series: Follow the World's Biggest Traders To See Where the Money Flows(The 5 Minute Wrapup)
Apr 17, 201920% of all the traders bring in 80% of the money. Watch these 20% and you get a working idea of which way the wind is blowing.
A Letter to You from India's No. 1 Trader(The 5 Minute Wrapup)
Apr 15, 2019It's our great pleasure to introduce Vijay Bhambwani to our readers - we consider Vijay to be India's best trader. Read on to find out why...
More|
| |
BIOCON SHARE PRICE
Apr 25, 2019 03:13 PM
TRACK BIOCON
- Track your investment in BIOCON with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON BIOCON
BIOCON 8-QTR ANALYSIS
COMPARE BIOCON WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.